ArticleOrphanet journal of rare diseases2025
French guidelines for the management of nonadvanced mastocytosis in adults.
Article in Orphanet journal of rare diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Mastocytosis is a rare disease caused by abnormal mast cell accumulation/proliferation in various organs/tissues. Its clinical features exhibit significant variability irrespective of its clinical presentation, classification, global survival or impact on quality of life (QOL). For example, 15% of adult patients present isolated skin mastocytosis, called cutaneous mastocytosis (CM), while 85% have systemic mastocytosis (SM), with the most frequent type of skin lesions being systemic mastocytosis with cutaneous infiltration. In addition, regardless of the location of the mast cells or whether the CM or SM is isolated (whether with or without associated skin involvement), symptoms due to mast cell activation can vary in severity and may be life-threatening. All these manifestations can impose additional stress on patients.This protocol is a compendium of evidence-based recommendations formulated by experts. Its purpose is to assist clinicians in the management of these rare and frequently complex diseases. It describes the management of adult patients with nonadvanced or indolent mastocytosis (CM), CM with primary MCAS, indolent systemic mastocytosis, bone marrow mastocytosis, and smoldering mastocytosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.